[Thromboprophylaxis in patients with coronary aneurysms caused by Kawasaki disease]

Area of Science:

• Cardiology
• Pediatric Rheumatology
• Hematology

Context:

• Kawasaki disease is a leading cause of acquired heart disease in children.
• Coronary artery aneurysms (CAAs) are a significant complication, leading to increased risk of thrombosis and ischemia.
• Current management relies on thromboprophylaxis, but robust clinical evidence is lacking.

Purpose:

• To review the current practices for thromboprophylaxis in patients with Kawasaki disease-associated coronary artery aneurysms.
• To highlight the commonly used anti-platelet agents and anticoagulants.
• To underscore the need for further research and randomized controlled trials.

Summary:

• Patients with Kawasaki disease and CAAs are at high risk for coronary thrombosis.
• Official guidelines recommend long-term thromboprophylaxis with anti-platelet agents (e.g., aspirin, clopidogrel) +/- warfarin.
• Aspirin, alone or with warfarin, is the most common regimen, despite limited data on efficacy.

Impact:

• Informs clinical practice regarding thromboprophylaxis in Kawasaki disease.
• Identifies gaps in evidence for current treatment strategies.
• Emphasizes the need for high-quality research to optimize patient outcomes and prevent thrombotic events.